SumMed Beta Program Terms & Conditions

1. Eligibility and Access

Participation in the SumMed Beta Program is by invitation only. Access is granted solely for testing and evaluation purposes and may be revoked at any time, for any reason, without notice.

2. License and Use

Participants are granted a limited, non-exclusive, non-transferable, revocable license to use SumMed solely for the duration of the beta program. Redistribution, reverse engineering, or unauthorized use is strictly prohibited.

3. Responsible Use & Legal Compliance

By participating, you agree to use SumMed responsibly and in accordance with all applicable local, national, and international laws and regulations, including but not limited to the EU AI Act and relevant medical device regulations. You must not use SumMed for any unlawful, unethical, or unauthorized purposes.

4. No Medical Advice

SumMed is not a substitute for professional medical advice, diagnosis, or treatment. The information provided is for informational support only and is intended to assist healthcare professionals and patients in understanding medical information. Always seek the advice of a qualified healthcare provider with any questions regarding medical conditions or care.

5. No Warranties; "As Is" Software

SumMed is provided "AS IS" and may contain bugs, errors, or incomplete features. We make no warranties, express or implied, regarding the software’s performance, reliability, or suitability for any purpose. Use of SumMed is entirely at your own risk.

6. No Service Level Agreements (SLAs)

No guarantees are made regarding the availability, uptime, support, or continued access to SumMed during the beta period. We may modify, suspend, or terminate the beta program at any time without liability.

7. Limitation of Liability

To the maximum extent permitted by law, we disclaim all liability for any damages, losses, or claims arising from your use of SumMed, including but not limited to data loss, business interruption, or any indirect or consequential damages.

8. Intellectual Property

All rights, title, and interest in SumMed, including all intellectual property, remain with the developer. Participation does not grant any ownership or rights beyond this agreement.

9. Feedback

Any feedback or suggestions provided may be used by us without obligation or compensation.

10. Term and Termination

This agreement is effective until the end of the beta program or until terminated by either party at any time, for any reason.

By participating, you acknowledge and accept these terms.